| Literature DB >> 21744477 |
Susanne Rogers1, Paul Donachie, Elaine Sugden, Geoffrey Sharpe, Martin English, Kath Robinson, Frank Saran.
Abstract
Hair loss was compared between surgery followed by craniospinal radiotherapy (CSRT) or chemotherapy then CSRT (C-CSRT) for medulloblastoma. The proportion of patients exhibiting hair loss in the cranial field was 70.0% (C-CSRT) versus 30.0% (CSRT) (95% CI: 14.7% to 58.9%; P = 0.002). The C-CSRT group also experienced more virtual/complete hair loss over the posterior fossa boost. Age was a significant contributor to hair loss in the cranial field. Persistent significant hair loss is an under-reported late effect of treatment that could influence quality of survival and should be considered in future trial design.Entities:
Mesh:
Year: 2011 PMID: 21744477 DOI: 10.1002/pbc.22992
Source DB: PubMed Journal: Pediatr Blood Cancer ISSN: 1545-5009 Impact factor: 3.167